Literature DB >> 31948859

Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series.

Swetha Kambhampati1, Lissa Gray2, Bita Fakhri3, Mimi Lo4, Khoan Vu3, Shagun Arora3, Lawry Kaplan3, Weiyun Z Ai3, Charalambos Andreadis3.   

Abstract

Entities:  

Keywords:  Cellular therapy; Checkpoint inhibitor; Diffuse large B cell lymphoma; Immune-related adverse events; Pembrolizumab

Mesh：

Substances：

Year:  2019        PMID： 31948859     DOI： 10.1016/j.clml.2019.12.014

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  6 in total

1.  Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.

Authors:  Elise A Chong; Cécile Alanio; Jakub Svoboda; Sunita D Nasta; Daniel J Landsburg; Simon F Lacey; Marco Ruella; Siddharth Bhattacharyya; E John Wherry; Stephen J Schuster
Journal:  Blood       Date:  2022-02-17       Impact factor: 25.476

2.  Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Authors:  Stefanie R Bailey; Sonika Vatsa; Rebecca C Larson; Amanda A Bouffard; Irene Scarfò; Michael C Kann; Trisha R Berger; Mark B Leick; Marc Wehrli; Andrea Schmidts; Harrison Silva; Kevin A Lindell; Ashley Demato; Kathleen M E Gallagher; Matthew J Frigault; Marcela V Maus
Journal:  Blood Cancer Discov       Date:  2022-03-01

Review 3.  Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Authors:  Rajshekhar Chakraborty; Brian T Hill; Aneela Majeed; Navneet S Majhail
Journal:  Transplant Cell Ther       Date:  2020-12-21

Review 4.  The Role of Immune Checkpoints after Cellular Therapy.

Authors:  Friederike Schmitz; Dominik Wolf; Tobias A W Holderried
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

5.  First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.

Authors:  François Anna; Elodie Bole-Richard; Joel LeMaoult; Marie Escande; Martin Lecomte; Jean-Marie Certoux; Philippe Souque; Francine Garnache; Olivier Adotevi; Pierre Langlade-Demoyen; Maria Loustau; Julien Caumartin
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

6.  Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.

Authors:  Chia-Ing Jan; Shi-Wei Huang; Shao-Chih Chiu; Der-Yang Cho; Peter Canoll; Jeffrey N Bruce; Yu-Chuan Lin; Chih-Ming Pan; Hsin-Man Lu
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.